Belgium Pharamceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	71
ISBN Number	not applicable
Product Code	BMI01653

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

Belgium's pharmaceutical market was worth US$4.89bn in 2007 and should grow steadily over the forecast period to reach a value of US$5.67bn by 2012. Patented drugs are the leading category, accounting for almost 80% of the market; however, generic drugs are the fastest-growing sector, as the government seeks to promote these products as part of cost-saving plans.

This focus on saving is beginning to pay of and this quarter the government announced that expenditure on reimbursed drugs remained within budget. This was primarily due to an increase in the uptake of lowcost drugs. In 2007, over 40% of prescriptions for reimbursed medicines were for low-cost pharmaceuticals. Breaking this down, generic medicines accounted for 23.54% of the total, while originator drugs that have lost their patents and have had their prices reduced accounted for 16.69%.

Meanwhile, drugmakers in Belgium should benefit from a European Commission (EC) decision to authorise a series of tax cuts introduced in the pharmaceutical sector. The breaks are aimed at firms that invest a high proportion of their sales in R&D or those that invest heavily in their production processes.

Belgium's major pharmaceutical players have recorded promising results for FY07, despite the general malaise in the industry.

However, Belgium's recent political instability, which has seen the threat of the country splitting into separate French-speaking and Flemish-speaking entities, has been very damaging. Regardless of the outcome over the coming month, BMI believes that it will take the political system and Belgium's international reputation a long time to recover from the affair. This view is reflected is reflected in the Business Environment Ranking for Western Europe, where Belgium remains in second last position.

Content

Executive Summary
Belgium Pharmaceuticals And Healthcare Industry SWOT
Belgium Political SWOT
Belgium Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Belgium - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Regime
Pricing And Reimbursement Developments
Industry Developments
Healthcare Sector
Health Profile
- Table: Main Causes Of Death
Recent Healthcare Sector Developments
Recent Company Developments
Generics Sector
Research And Development Sector
Janssen Under Pressure
Industry Forecast Sce27
Overall Market Forecast
- Table: Belgium Drug Market Forecast Indicators
Key Growth Factors - Industry
- Table: Health Expenditure Indicators
Key Growth Factors - Macroeconomic
- Table: Belgium - Macroeconomic Forecasts
Patented Market Forecast
- Table: Belgium Prescription Drugs Market Forecast Ind
OTC Market Forecast
- Table: Belgium OTC Drugs Market Forecast Indicators
Generics And Branded Market
- Table: Belgium Generics And Branded Drug Market Forecast Indicators
Export/Import Forecasts
- Table: Belgium Pharmaceuticals Exports And Imports
Other Healthcare Data Forecasts
- Table: Belgium Healthcare Data Forecast Indicators
Key Risks To BMI's Forecasts
Competitive Landscape
Company Monitor
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
Janssen Pharmaceutica
Leading Indigenous Manufacturers
UCB Pharma
Solvay
Omega Pharma
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources